Joshua D. Kidd

673 total citations
11 papers, 504 citations indexed

About

Joshua D. Kidd is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Joshua D. Kidd has authored 11 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 6 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in Joshua D. Kidd's work include Amyotrophic Lateral Sclerosis Research (10 papers), Neurogenetic and Muscular Disorders Research (6 papers) and Parkinson's Disease Mechanisms and Treatments (3 papers). Joshua D. Kidd is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (10 papers), Neurogenetic and Muscular Disorders Research (6 papers) and Parkinson's Disease Mechanisms and Treatments (3 papers). Joshua D. Kidd collaborates with scholars based in United States and Switzerland. Joshua D. Kidd's co-authors include Fernando G. Vieira, Alan Gill, Kenneth Thompson, Theo Hatzipetros, Steven Perrin, Beth Levine, Monica Z. Wang, John Lincecum, Andrew Moreno and Cathleen Lutz and has published in prestigious journals such as Nature Genetics, PLoS ONE and Scientific Reports.

In The Last Decade

Joshua D. Kidd

11 papers receiving 485 citations

Peers

Countries citing papers authored by Joshua D. Kidd

Since Specialization

Citations

This map shows the geographic impact of Joshua D. Kidd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua D. Kidd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua D. Kidd more than expected).

Fields of papers citing papers by Joshua D. Kidd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua D. Kidd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua D. Kidd. The network helps show where Joshua D. Kidd may publish in the future.

Co-authorship network of co-authors of Joshua D. Kidd

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua D. Kidd. A scholar is included among the top collaborators of Joshua D. Kidd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua D. Kidd. Joshua D. Kidd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	PERK modulation, with GSK2606414, Sephin1 or salubrinal, failed to produce therapeutic benefits in the SOD1G93A mouse model of ALS 2024 ·PLoS ONE ·Fernando G. Vieira, (unknown), Joshua D. Kidd, Andrew Moreno, Kenneth Thompson, Steven Perrin, Alan Gill, Theo Hatzipetros	1
2	SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS 2019 ·Scientific Reports ·(unknown), (unknown), Theo Hatzipetros, Joshua D. Kidd, (unknown), Beth Levine, Monica Z. Wang, Andrew Moreno, Kenneth Thompson, Marcel Maier, Jan Grimm, Alan Gill, Fernando G. Vieira	50
3	CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits 2017 ·IBRO Reports ·Fernando G. Vieira, Theo Hatzipetros, Kenneth Thompson, (unknown), Joshua D. Kidd, (unknown), Beth Levine, Steven Perrin, Alan Gill	32
4	A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS 2015 ·Journal of Visualized Experiments ·Theo Hatzipetros, Joshua D. Kidd, (unknown), Kenneth Thompson, Alan Gill, Fernando G. Vieira	73
5	Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS 2015 ·PLoS ONE ·Fernando G. Vieira, (unknown), (unknown), Joshua D. Kidd, Kenneth Thompson, Bingbing Jiang, John Lincecum, Monica Z. Wang, (unknown), (unknown), Beth Levine, Theo Hatzipetros, Alan Gill, Steven Perrin	64
6	A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS 2015 ·Journal of Visualized Experiments ·Theo Hatzipetros, Joshua D. Kidd, (unknown), Kenneth W. Thompson, Alan Gill, Fernando G. Vieira	16
7	Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration 2014 ·PLoS ONE ·Fernando G. Vieira, (unknown), (unknown), Joshua D. Kidd, Beth Levine, Kenneth Thompson, Alan Gill, Steven Finkbeiner, Steven Perrin	23
8	A Comparison of R-line Photoluminescence of Emeralds from Different Origins 2014 ·Journal of gemmology/The journal of gemmology ·(unknown), Joshua D. Kidd, (unknown), (unknown), Christopher P. Smith	7
9	C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS 2013 ·Brain Research ·Theo Hatzipetros, Laurent Bogdanik, (unknown), Joshua D. Kidd, (unknown), Crystal Davis, Melissa Osborne, Andrew D. Austin, Fernando G. Vieira, Cathleen Lutz, Steve Perrin	76
10	From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis 2010 ·Nature Genetics ·John Lincecum, Fernando G. Vieira, Monica Z. Wang, Kenneth Thompson, (unknown), Joshua D. Kidd, Andrew Moreno, Ricardo Sànchez, (unknown), Beth Levine, (unknown), (unknown), Alan Gill, Steven Perrin	96
11	No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS 2009 ·PLoS ONE ·Alan Gill, Joshua D. Kidd, Fernando G. Vieira, Kenneth Thompson, Steven Perrin	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact